233 related articles for article (PubMed ID: 35763157)
1. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.
Lee CM; Kang P; Cho CK; Park HJ; Lee YJ; Bae JW; Choi CI; Kim HS; Jang CG; Lee SY
Arch Pharm Res; 2022 Jun; 45(6):433-445. PubMed ID: 35763157
[TBL] [Abstract][Full Text] [Related]
2. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 May; 47(5):481-504. PubMed ID: 38664354
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.
Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2021 Nov; 44(11):1037-1049. PubMed ID: 34751931
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Chen Y; Zhou D; Tang W; Zhou W; Al-Huniti N; Masson E
J Clin Pharmacol; 2018 Apr; 58(4):485-493. PubMed ID: 29193123
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.
Jin SK; Chung HJ; Chung MW; Kim JI; Kang JH; Woo SW; Bang S; Lee SH; Lee HJ; Roh J
J Clin Pharm Ther; 2008 Oct; 33(5):567-73. PubMed ID: 18834373
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic (PBPK) modeling to predict the pharmacokinetics of irbesartan in different CYP2C9 genotypes.
Cho CK; Kang P; Jang CG; Lee SY; Lee YJ; Choi CI
Arch Pharm Res; 2023 Dec; 46(11-12):939-953. PubMed ID: 38064121
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.
Kim SH; Byeon JY; Kim YH; Lee CM; Lee YJ; Jang CG; Lee SY
Sci Rep; 2018 Aug; 8(1):12405. PubMed ID: 30120390
[TBL] [Abstract][Full Text] [Related]
9. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.
Rau T; Heide R; Bergmann K; Wuttke H; Werner U; Feifel N; Eschenhagen T
Pharmacogenetics; 2002 Aug; 12(6):465-72. PubMed ID: 12172215
[TBL] [Abstract][Full Text] [Related]
10. Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients.
Taguchi M; Nozawa T; Mizumaki K; Inoue H; Tahara K; Takesono C; Hashimoto Y
Biol Pharm Bull; 2004 Oct; 27(10):1642-8. PubMed ID: 15467211
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.
Byeon JY; Kim YH; Lee CM; Kim SH; Chae WK; Jung EH; Choi CI; Jang CG; Lee SY; Bae JW; Lee YJ
Arch Pharm Res; 2018 Sep; 41(9):921-930. PubMed ID: 30191460
[TBL] [Abstract][Full Text] [Related]
12. Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.
Qian J; Xu T; Pan P; Sun W; Hu G; Cai J
Pharmacogenomics J; 2024 Apr; 24(3):13. PubMed ID: 38637522
[TBL] [Abstract][Full Text] [Related]
13. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4.
Gaohua L; Abduljalil K; Jamei M; Johnson TN; Rostami-Hodjegan A
Br J Clin Pharmacol; 2012 Nov; 74(5):873-85. PubMed ID: 22725721
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.
Huang J; Chuang SK; Cheng CL; Lai ML
Clin Pharmacol Ther; 1999 Apr; 65(4):402-7. PubMed ID: 10223777
[TBL] [Abstract][Full Text] [Related]
15. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
Thomas CD; Mosley SA; Kim S; Lingineni K; El Rouby N; Langaee TY; Gong Y; Wang D; Schmidt SO; Binkley PF; Estores DS; Feng K; Kim H; Kinjo M; Li Z; Fang L; Chapman AB; Cooper-DeHoff RM; Gums JG; Hamadeh IS; Zhao L; Schmidt S; Frye RF; Johnson JA; Cavallari LH
CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):678-685. PubMed ID: 33067866
[TBL] [Abstract][Full Text] [Related]
16. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Ismail R; Teh LK
J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
Blake CM; Kharasch ED; Schwab M; Nagele P
Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
[TBL] [Abstract][Full Text] [Related]
18. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate.
Seeringer A; Brockmöller J; Bauer S; Kirchheiner J
Eur J Clin Pharmacol; 2008 Sep; 64(9):883-8. PubMed ID: 18545991
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
20. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]